Medication Safety and Quality
COVID-19 medication-related issues
The Clinical Excellence Commission's Medication Safety Team has created medication-related resources specific to COVID-19 for health professionals.
- Dexamethasone Factsheet (Updated 21 July 2020)
- Safe handling of medications in COVID-19 pandemic (Added 14 May 2020)
- Hydroxychloroquine Factsheet (Updated 12 May 2020)
- Lopinavir/Ritonavir (Kaletra®) (Updated 12 May 2020)
- Approval Process of Medicines for Use in NSW Public Hospitals
- AMS Expert Advisory Committee Position Statement – Supply of medicines being used in COVID-19 (Updated 26 May 2020)
Medication safety updates
Medication safety communication
- Olmesartan - 27 July 2020
- Methotrexate injection - 16 July 2020
- Triamcinolone acetonide injection – Revised 29 June 2020
- Amoxicillin/Clavulanic Acid IV Injection – 4 June 2020
- Suxamethonium chloride 100 mg/2 mL – 27 May 2020
- Adrenaline 1:1,000 – Updated 21 May 2020
- Dobutamine hydrochloride 250mg/20 mL – 15 May 2020
- Pristinamycin (SAS) 500mg – 14 May 2020
- Gentamicin 10mg/1mL – 28 April 2020
- Cisatracurium – 21 April 2020
- Adrenaline 1:10,000 – 19 March 2020
- Gentamicin 80mg/2mL – 13 March 2020
- Trimethoprim-sulfamethoxazole 80mg/400mg – Resolved as of 25 May 2020
Medication Safety and Quality
Use of medicines is one of the most common therapeutic interventions in Australian hospitals. It is also one of the most complex, with delivery of each dose of medicine involving as many as 30 steps and almost as many people. Because they are so commonly used, medicines are associated with a higher incidence of errors and adverse events than other healthcare interventions.
Medication incidents have been estimated to cost the Australian health care system more than $660 million per year and represent 27% of all clinical incidents occurring in Australian hospitals , . In NSW, medication and intravenous fluid related incidents are the second most frequently reported incident type, with a significant number of these incidents resulting in patient harm .
The Medication Safety and Quality unit supports the safe and quality use of medicines by identifying and addressing emerging medication safety risks. Continuity of Medication Management, High-Risk Medicines, Medication Safety Self Assessment (MSSA) and VTE Prevention are Medication Safety and Quality programs that assist health care teams to work together and improve their local medicines-use systems.
The Continuity of Medication Management program provides tools and resources to support medication reconciliation - the process of ensuring that patients receive all intended medicines and that accurate, current and comprehensive medicine information follows them at all transfers of care.
The High-Risk Medicines program aims to heighten awareness of the harm that can be caused and provide action-oriented information that will assist in improvements to the management of high-risk medicines in hospitals in NSW.
The Medication Safety Self Assessment (MSSA) and associated tools were designed to facilitate evaluation of systems and processes related to medicines use and highlight opportunities for improvement. The CEC has adapted these for Australian hospitals.
The VTE Prevention program assists health care facilities and clinical teams to implement robust processes for the prevention of hospital-associated venous thromboembolism (VTE). It provides clinicians and health professionals with the tools and resources required to address this patient safety issue. For further information on this program please contact the Medication Safety team.
Each program provides tools and resources to make medicine use safer and to assist health services meet the requirements of the National Safety and Quality Health Service Standard 4 - Medication Safety.
Other Medication Safety and Quality Projects and Initiatives
Additional campaigns, projects and initiatives that support medication safety and quality improvement include:
- Pharmacy Barcode Scanning - barcode scanning has been shown to reduce the rate of pharmacy dispensing errors.
- Tall Man Lettering - uses a combination of lower and upper case letters to highlight the differences between look-alike medicine names, helping to make them more easily distinguishable.
- Revisions to the National Inpatient Medication Chart - the NIMC is a fundamental element in patient safety. This project highlights recent revisions to the chart.
- User-Applied Labelling - provides information and links on the requirements for user-applied labelling in NSW Public Health Organisations and NSW Ambulance.
 Roughead, E., & Semple, S. Medication safety in acute care in Australia: where are we now? Part 1: a review of the extent and causes of medication problems 2002-2008. Australia and New Zealand Health Policy. 2009: 6(1):18.
 Runciman, W., Roughead,E., Semple, S., & Adams, R. Adverse drug events and medication errors in Australia. International Journal for Quality in Health Care. 2003; 15(suppl 1): i49-i59.
 Clinical Excellence Commission. Clinical Incident Management in the NSW Public Health System 2009: July to December.2011. Sydney: Clinical Excellence Commission.